What is methamphetamine?
Methamphetamine is a stimulant drug usually used as a white, bitter-tasting powder or a pill. Crystal methamphetamine is a form of the drug that looks like glass fragments or shiny, bluish-white rocks. It is chemically similar to amphetamine [a drug used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy, a sleep disorder].
Other common names for methamphetamine include chalk, crank, crystal, ice, meth, and speed.
How do people use methamphetamine?
People can take methamphetamine by:
- swallowing (pill)
- injecting the powder that has been dissolved in water/alcohol
Because the "high" from the drug both starts and fades quickly, people often take repeated doses in a "binge and crash" pattern. In some cases, people take methamphetamine in a form of binging known as a "run," giving up food and sleep while continuing to take the drug every few hours for up to several days.
How does methamphetamine affect the brain?
Methamphetamine increases the amount of the natural chemical dopamine in the brain. Dopamine is involved in body movement, motivation, pleasure, and reward (pleasure from natural behaviors such as eating). The drug’s ability to release high levels of dopamine rapidly in reward areas of the brain produces the "rush" (euphoria) or "flash" that many people experience.
Taking even small amounts of methamphetamine can result in many of the same health effects as those of other stimulants, such as cocaine or amphetamines. These include:
- increased wakefulness and physical activity
- decreased appetite
- faster breathing
- rapid and/or irregular heartbeat
- increased blood pressure and body temperature
How Do Manufacturers Make Methamphetamine?
Manufacturers make most of the methamphetamine found in the United States in "superlabs" here or, more often, in Mexico. But some also make the drug in small, secret labs with inexpensive over-the-counter ingredients such as pseudoephedrine, a common ingredient in cold medicines. To curb production, the law requires pharmacies and other retail stores to keep a purchase record of products containing pseudoephedrine. A person may only buy a limited amount of those products on a single day.
What are other health effects of methamphetamine?
People who inject methamphetamine are at increased risk of contracting infectious diseases such as HIV and hepatitis B and C. These diseases are transmitted through contact with blood or other bodily fluids. Methamphetamine use can also alter judgment and decision-making leading to risky behaviors, such as unprotected sex, which also increases risk for infection.
Methamphetamine use may worsen the progression of HIV/AIDS and its consequences. Studies indicate that HIV causes more injury to nerve cells and more cognitive problems in people who have HIV and use methamphetamine than it does in people who have HIV and don't use the drug.1 Cognitive problems are those involved with thinking, understanding, learning, and remembering.
Long-term methamphetamine use has many other negative consequences, including:
- extreme weight loss
- severe dental problems ("meth mouth")
- intense itching, leading to skin sores from scratching
- sleeping problems
- violent behavior
- paranoia—extreme and unreasonable distrust of others
- hallucinations—sensations and images that seem real though they aren't
In addition, continued methamphetamine use causes changes in the brain's dopamine system that are associated with reduced coordination and impaired verbal learning. In studies of people who used methamphetamine over the long term, severe changes also affected areas of the brain involved with emotion and memory.2 This may explain many of the emotional and cognitive problems observed in those who use methamphetamine.
Although some of these brain changes may reverse after being off the drug for a year or more, other changes may not recover even after a long period of abstinence.3 A recent study even suggests that people who used methamphetamine have an increased the risk of developing Parkinson's disease, a disorder of the nerves that affects movement.4
Are there health effects from exposure to secondhand methamphetamine smoke?
Researchers don't yet know whether people breathing in secondhand methamphetamine smoke can get high or have other health effects. What they do know is that people can test positive for methamphetamine after exposure to secondhand smoke.5,6 More research is needed in this area.
Can a person overdose on methamphetamine?
Yes, a person can overdose on methamphetamine. An overdose occurs when the person uses too much of a drug and has a toxic reaction that results in serious, harmful symptoms or death.
Methamphetamine overdose can lead to stroke, heart attack, or organ problems—such as kidney failure—caused by overheating. These conditions can result in death.
How can a methamphetamine overdose be treated?
Because methamphetamine overdose often leads to a stroke, heart attack, or organ problems, first responders and emergency room doctors try to treat the overdose by treating these conditions, with the intent of:
- restoring blood flow to the affected part of the brain (stroke)
- restoring blood flow to the heart (heart attack)
- treating the organ problems
Is methamphetamine addictive?
Yes, methamphetamine is highly addictive. When people stop taking it, withdrawal symptoms can include:
- severe depression
- intense drug cravings
How can people get treatment for methamphetamine addiction?
The most effective treatments for methamphetamine addiction so far are behavioral therapies, such as:
- cognitive-behavioral therapy, which helps patients recognize, avoid, and cope with the situations in which they are most likely to use drugs
- motivational incentives, which uses vouchers or small cash rewards to encourage patients to remain drug-free
While research is under way, there are currently no government-approved medications to treat methamphetamine addiction.
Points to Remember
- Methamphetamine is usually a white, bitter-tasting powder or a pill. Crystal methamphetamine looks like glass fragments or shiny, bluish-white rocks.
- Methamphetamine is a stimulant drug that is chemically similar to amphetamine (a drug used to treat ADHD and narcolepsy).
- People can take methamphetamine by inhaling/smoking, swallowing, snorting, or injecting the drug.
- Methamphetamine increases the amount of dopamine in the brain, which is involved in body movement, motivation, pleasure, and reward.
- Short-term health effects include increased wakefulness and physical activity, decreased appetite, and increased blood pressure and body temperature.
- Long-term health effects include risk of contracting HIV and hepatitis; severe dental problems ("meth mouth"); intense itching, leading to skin sores from scratching; violent behavior; and paranoia.
- Researchers don't yet know whether people breathing in secondhand methamphetamine smoke can get high or have other health effects.
- A person can overdose on methamphetamine. Because methamphetamine overdose often leads to a stroke, heart attack, or organ problems, first responders and emergency room doctors try to treat the overdose by treating these conditions.
- Methamphetamine is highly addictive. When people stop taking it, withdrawal symptoms can include anxiety, fatigue, severe depression, psychosis, and intense drug cravings.
- The most effective treatments for methamphetamine addiction so far are behavioral therapies. There are currently no government-approved medications to treat methamphetamine addiction.
For more information about methamphetamine, visit our:
- Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162(2):361-369. doi:10.1176/appi.ajp.162.2.361.
- Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377-382. doi:10.1176/appi.ajp.158.3.377.
- Wang G-J, Volkow ND, Chang L, et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161(2):242-248. doi:10.1176/appi.ajp.161.2.242.
- Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30-38. doi:10.1016/j.drugalcdep.2014.10.027.
- Bassindale T. Quantitative analysis of methamphetamine in hair of children removed from clandestine laboratories--evidence of passive exposure? Forensic Sci Int. 2012;219(1-3):179-182. doi:10.1016/j.forsciint.2012.01.003.
- Farst K, Reading Meyer JA, Mac Bird T, James L, Robbins JM. Hair drug testing of children suspected of exposure to the manufacture of methamphetamine. J Forensic Leg Med. 2011;18(3):110-114. doi:10.1016/j.jflm.2011.01.013.
This publication is available for your use and may be reproduced in its entirety without permission from the NIDA. Citation of the source is appreciated, using the following language: Source: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services.
1. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2007.
2. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2008.
3. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2009.
4. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2010.
5. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2011.
6. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2012.
7. United Nations Office on Drugs and Crime Vienna. World Drug Report 2007. New York, NY: United Nations; 2013.
8. Newton TF, Cook IA, Kalechstein AD, Duran S, Monroy F, Ling W, et al. Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol. 2003;114(3):410–5.[PubMed]
9. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15(3):317–25.[PubMed]
10. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24(26):6028–36.[PubMed]
11. Rangwala Z. Hypotension in Chronic Methamphetamine User. Clinical Anesthesiology. 2014:187–91.
12. Richards CF, Clark RF, Holbrook T, Hoyt DB. The effect of cocaine and amphetamines on vital signs in trauma patients. J Emerg Med. 1995;13(1):59–63.[PubMed]
13. Cook CE, Jeffcoat AR. Pyrolytic degradation of heroin, phencyclidine, and cocaine: identification of products and some observations on their metabolism. NIDA Res Monogr. 1990;99:97–120.[PubMed]
14. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther. 2003;74(5):475–86.[PubMed]
15. Schepers RJ, Oyler JM, Joseph RE, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003;49(1):121–32.[PubMed]
16. Alam MZ, Noroozi A. An emerging trend of methamphetamine injection in iran: a critical target for research on blood-borne infection diseases. Hepat Mon. 2013;13(2):e8154.[PMC free article][PubMed]
17. Noroozi A, Radfar R, Motavalian A. Results of Bio Behavioral Survey among Injecting Drug Users and their Spouses in 3 large City of Iran. 2013
18. Radfar R, Noroozi A, Tayeri K, Motavalian A. Study on situation of HIV, Latent Tuberculosis (TB) and Active TB Infection among Injecting Drug Users Receiving Harm Reduction Services in Tehran and 5 large cities in Iran. 2014
19. American Psychiatric Association. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC: American Psychiatric Association; 2000. Diagnostic and Statistical Manual of Mental Disorders. pp. 85–93.
20. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100(9):1320–9.[PubMed]
21. Cantwell B, McBride AJ. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend. 1998;49(2):157–63.[PubMed]
22. Churchill AC, Burgess PM, Pead J, Gill T. Measurement of the severity of amphetamine dependence. Addiction. 1993;88(10):1335–40.[PubMed]
23. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004;13(3):248–55.[PubMed]
24. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17(3):275–97.[PubMed]
25. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161(2):242–8.[PubMed]
26. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increases extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.[PubMed]
27. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181–90.[PubMed]
28. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med. 1999;170(4):198–202.[PMC free article][PubMed]
29. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med. 1999;170(4):214–9.[PMC free article][PubMed]
30. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000;9(1):28–37.[PubMed]
31. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101(10):1473–8.[PubMed]
32. Chen CK, Lin SK, Sham PC, Ball D, Loh E, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2005;136B(1):87–91.[PubMed]
33. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407–14.[PubMed]
34. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand. 1994;89(6):428–32.[PubMed]
35. Matsumoto T, Tachimori H, Tanibuchi Y, Takano A, Wada K. Clinical features of patients with designer-drug-related disorder in Japan: A comparison with patients with methamphetamine- and hypnotic/anxiolytic-related disorders. Psychiatry Clin Neurosci. 2014;68(5):374–82.[PubMed]
36. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102(Suppl 1):130–5.[PubMed]
37. Halkitis PN, Solomon TM, Moeller RW, Doig SA, Espinosa LS, Siconolfi D, et al. Methamphetamine use among gay, bisexual and non-identified men-who-have-sex-with-men: an analysis of daily patterns. J Health Psychol. 2009;14(2):222–31.[PubMed]
38. Halkitis PN, Moeller RW, Pollock JA. Sexual practices of gay, bisexual and other nonidentified MSM attending New York City gyms: patterns of serosorting, strategic positioning, and context selection. J Sex Res. 2008;45(3):253–61.[PubMed]
39. Reback CJ, Shoptaw S, Grella CE. Methamphetamine use trends among street-recruited gay and bisexual males, from 1999 to 2007. J Urban Health. 2008;85(6):874–9.[PMC free article][PubMed]
40. Halkitis PN. Methamphetamine addiction: biological foundations, psychological factors, and social consequences. Washington, DC: American Psychological Association; 2009.
41. Kurtz SP. Post-circuit blues: motivations and consequences of crystal meth use among gay men in Miami. AIDS Behav. 2005;9(1):63–72.[PubMed]
42. Shoptaw S, Weiss RE, Munjas B, Hucks-Ortiz C, Young SD, Larkins S, et al. Homonegativity, substance use, sexual risk behaviors, and HIV status in poor and ethnic men who have sex with men in Los Angeles. J Urban Health. 2009;86(Suppl 1):77–92.[PMC free article][PubMed]
43. Liao M, Jiang Z, Zhang X, Kang D, Bi Z, Liu X, et al. Syphilis and methamphetamine use among female sex workers in Shandong Province, China. Sex Transm Dis. 2011;38(1):57–62.[PubMed]
44. Loza O, Strathdee SA, Martinez GA, Lozada R, Ojeda VD, Staines-Orozco H, et al. Risk factors associated with chlamydia and gonorrhoea infection among female sex workers in two Mexico-USA border cities. Int J STD AIDS. 2010;21(7):460–5.[PMC free article][PubMed]
45. Miller CL, Kerr T, Fischer B, Zhang R, Wood E. Methamphetamine injection independently predicts hepatitis C infection among street-involved youth in a Canadian setting. J Adolesc Health. 2009;44(3):302–4.[PMC free article][PubMed]
46. Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009;(2):CD003021.[PubMed]
47. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009;(1):CD003026.[PubMed]
48. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005;88(Suppl 3):S43–S52.[PubMed]
49. Ling W, Rawson R, Shoptaw S, Ling W. Management of methamphetamine abuse and dependence. Curr Psychiatry Rep. 2006;8(5):345–54.[PubMed]
50. Coffin PO, Santos GM, Das M, Santos DM, Huffaker S, Matheson T, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108(4):751–61.[PMC free article][PubMed]
51. Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav. 2004;29(7):1439–64.[PubMed]
52. Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users. Drug Alcohol Rev. 2002;21(2):179–85.[PubMed]
53. Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse. 2014;40(1):10–5.[PubMed]
54. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708–17.[PubMed]
55. Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101(2):267–74.[PubMed]
56. Ghasemi A, Eftekhari Ardebili M, Foroshani Rahimi A, Tol A, Taghdisi MH. Effect of Empowerment Based Intervention Program on Promoting Lifestyle among Methamphetamine Addict and Their Families Compare with Non-Addicts. World Applied Sciences Journal. 2013;22(2):270–5.
57. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33(5):1162–70.[PubMed]
58. Get Immediate Treatment Help. Harm Reduction History and Definitions [Online]. 2007. Available from: URL: http://www.addictioninfo.org/articles/256/1/Harm-Reduction-History-and-Definitions/Page1.html.
59. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex. 2001;41(2):17–35.[PubMed]
60. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007;45(1):85–92.[PMC free article][PubMed]
61. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168(2):93–7.[PMC free article][PubMed]
62. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006;83(6):1151–7.[PMC free article][PubMed]
63. Hunter C, Barnaby L, Busch A, Marshall C, Shepherd S, Strike C. Determining the harm reduction services required for safer crystal methamphetamine smoking in Toronto. Toronto, ON: Crystal methamphetamine smokers in Toronto, Ontario; 2011. [PMC free article][PubMed]
64. Darke S, Torok M, Kaye S, Ross J, McKetin R. Comparative rates of violent crime among regular methamphetamine and opioid users: offending and victimization. Addiction. 2010;105(5):916–9.[PubMed]
65. Gizzi MC, Gerkin P. Methamphetamine use and criminal behavior. Int J Offender Ther Comp Criminol. 2010;54(6):915–36.[PubMed]
66. Sommers I, Baskin D. Methamphetamine use and Violence. Journal of Drug Issues. 2006;36(1):77–96.
67. Cartier J, Farabee D, Prendergast ML. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J Interpers Violence. 2006;21(4):435–45.[PubMed]
68. Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. AIDS Educ Prev. 2003;15(3):257–68.[PubMed]
69. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee S, et al. The Global Epidemiology of Methamphetamine Injection: A Review of the Evidence on Use and Associations with HIV and Other Harm. Sydney, Australia: National Drug & Alcohol Research Centre; 2007.
70. Cohn AM, Hunter-Reel D, Hagman BT, Mitchell J. Promoting behavior change from alcohol use through mobile technology: the future of ecological momentary assessment. Alcohol Clin Exp Res. 2011;35(12):2209–15.[PMC free article][PubMed]
71. Kelly JD, Giordano TP. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(8):1137–9.[PubMed]
72. Mukund Bahadur KC, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. Stud Health Technol Inform. 2010;160(Pt 1):530–4.[PubMed]